MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GRDN stock logo

GRDN

Guardian Pharmacy Services, Inc.

$37.99
0.37
 (0.98%)
[ms_data_label text=’Delayed data’]
Exchange:  NYSE
Market Cap:  2.406B
Shares Outstanding:  60.844M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Distribution
   
CEO:  Fred Burke
Full Time Employees:  3400
Address: 
300 Galleria Parkway SE
Atlanta
GA
30339
US
Website:  https://guardianpharmacy.com
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/03/11 — 4 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,046,1931,228,4091,448,685
Gross Profit208,310244,371282,042
EBITDA58,813-43,427111,249
Operating Income40,946-62,92088,914
Net Income23,902-87,28749,219

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets271,165320,810412,658
Total Liabilities211,306170,834194,734
Total Stockholders Equity0142,671217,924
Total Debt61,00130,1337,150
Cash and Cash Equivalents7524,66065,619

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow70,81957,960100,293
Capital Expenditure-14,556-16,368-19,583
Free Cash Flow56,26341,59280,710
Net Income37,720-71,03349,219
Net Change in Cash1453,90860,959

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,663,431.707Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,701,666.388Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,683,419Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)76,961.999Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)78,731.003Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)77,886.751Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)91,318.127Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)93,509.474Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)92,413.801Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)291,043.600Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)297,733.360Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)294,540.692Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.460Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.480Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.440Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)2Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.228B  ?P/S
 (TTM)
: 
1.63
?Net Income
 (TTM)
: 
-110047000  ?P/E
 (TTM)
: 
48.08
?Enterprise Value
 (TTM)
: 
2.346B  ?EV/FCF
 (TTM)
: 
29.07
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.28  ?ROIC
 (TTM)
: 
0.22
?Net Debt
 (TTM)
: 
32.672M  ?Debt/Equity
 (TTM)
: 
0.22
?P/B
 (TTM)
: 
11.5  ?Current Ratio
 (TTM)
: 
1.38

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
30.89Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates GRDN intrinsic value between $9.17 – $9.87 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GRDN Intrinsic Value

Common questions about GRDN valuation

Is Guardian Pharmacy Services, Inc. (GRDN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Guardian Pharmacy Services, Inc. (GRDN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GRDN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GRDN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GRDN’s P/E ratio?

You can see GRDN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GRDN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GRDN a good long-term investment?

Whether GRDN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

GRDN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0.98
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 19.17   Year High: 38.71
Price Avg 50: 33.54   Price Avg 200: 27.95
Volume: 511038   Average Volume: 407704

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Guardian Pharmacy Services, Inc. to Participate in the Bank of America 2026 Healthcare Conference
23-04-2026 17:00
Guardian Pharmacy Services, Inc. to Participate in the Bank of America 2026 Healthcare Conference
Guardian Pharmacy Services, Inc. to Report First Quarter 2026 Financial Results and Host Conference Call
14-04-2026 16:30
Guardian Pharmacy Services, Inc. to Report First Quarter 2026 Financial Results and Host Conference Call
Earnings Estimates Moving Higher for Guardian Pharmacy (GRDN): Time to Buy?
02-04-2026 13:21
Earnings Estimates Moving Higher for Guardian Pharmacy (GRDN): Time to Buy?
Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
18-03-2026 16:20
Guardian Pharmacy Services Announces Launch of Underwritten Public Offering of Class A Common Stock
All You Need to Know About Guardian Pharmacy (GRDN) Rating Upgrade to Buy
05-03-2026 13:00
All You Need to Know About Guardian Pharmacy (GRDN) Rating Upgrade to Buy
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference
12-02-2026 16:30
Guardian Pharmacy Services, Inc. to Participate in Upcoming Raymond James Institutional Investor Conference

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read